Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.

Efstathios Kastritis, MD, Athanasios Anagnostopoulos, MD, Maria Roussou, MD, Savvas Toumanidis, MD, Constantinos Pamboukas, MD, Anna Tassidou, MD, Irini Xilouri, MD, Sossana Delimpassi, MD, Erasmia Psimenou, MD, Sofia Mellou, MD, Evangelos Terpos, MD, John Nanas, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 191.

https://doi.org/10.1182/blood.V110.11.191.191

Published: 2007

Journal Articles

The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM).

Blood (2007) 110 (11): 1490.

https://doi.org/10.1182/blood.V110.11.1490.1490

Published: 2007

Journal Articles

Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments.

Maria Roussou, MD, Efstathios Kastritis, MD, Athanasios Anagnostopoulos, MD, Evangelos Eleftherakis-Papaiakovou, MD, Charis Matsouka, MD, Despina Barmparousi, MD, Magdalini Migkou, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 4812.

https://doi.org/10.1182/blood.V110.11.4812.4812

Published: 2007

Journal Articles

Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens.

Maria Roussou, MD, Efstathios Kastritis, MD, Athanasios Anagnostopoulos, MD, Erasmia Psimenou, MD, Irini Grapsa, MD, Charis Matsouka, MD, Despina Barmparousi, MD, Evangelos Terpos, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 2739.

https://doi.org/10.1182/blood.V110.11.2739.2739

Published: 2007

Journal Articles

Long-Term Follow-Up of Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) for Patients (pts) with Chronic Myeloid Leukemia (CML).

Partow Kebriaei, MD, Michelle Detry, PhD, Antonio Carrasco-Yalan, MD, Athanasios Anagnostopoulos, MD, Daniel Couriel, MD, Issa Khouri, MD, Paolo Anderlini, MD, Chitra Hosing, MD, Amin Alousi, MD, Sergio Giralt, MD, Richard Champlin, MD, Marcos de Lima, MD

Blood (2006) 108 (11): 2898.

https://doi.org/10.1182/blood.V108.11.2898.2898

Published: 2006

Journal Articles

Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenastrom’s Macroglobulinemia (WM): Correlations with Clinical Data.

Athanasios Anagnostopoulos, MD, Evangelos Terpos, M.D., Konstantinos Zervas, M.D., Efstathios Kastritis, M.D., Vangelis Eleftherakis-Papaiakovou, M.D., Irini Katodritou, M.D., Konstantinos Tsionos, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 5006.

https://doi.org/10.1182/blood.V108.11.5006.5006

Published: 2006

Journal Articles

Treatment of Low-Grade Non-Hodgkin Lymphomas with Fludarabine and Mitoxantrone Followed by Rituximab Maintenance: Results of a Phase II Study.

Amanda Psyrri, MD, Meletios A. Dimopoulos, MD, George Fountzilas, MD, Constantinos Tsatalas, MD, Athanasios Anagnostopoulos, MD, Sotirios Papageorgiou, MD, Nikolaos Xiros, MD, Theofanis Economopoulos, MD

Blood (2006) 108 (11): 4716.

https://doi.org/10.1182/blood.V108.11.4716.4716

Published: 2006

Journal Articles

Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT).

Athanasios Anagnostopoulos, MD, Lia A. Moulopoulos, M.D., Maria Roussou, M.D., Efstathios Kastritis, M.D., Dimitra Gika, George Bozas, M.D., Aikaterini Stefanoudaki, M.D., Nikolaos Anagnostopoulos, M.D., Amalia Vassou, M.D., Konstantinos Bourantas, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 3095.

https://doi.org/10.1182/blood.V108.11.3095.3095

Published: 2006

Journal Articles

Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens.

Betul Oran, MD, Sergio Giralt, MD, Munir Shahjahan, MD, Athanasios Anagnostopoulos, MD, Daniel Couriel, MD, Partow Kebriaei, MD, Chitra Hosing, MD, Shubhra Ghosh, MD, Ernesto de Meis, MD, Michele Donato, MD, Touch Ativivas, MD, Antonio Carrasco-Yalan, MD, Richard Champlin, MD, Marcos de Lima, MD

Blood (2005) 106 (11): 2019.

https://doi.org/10.1182/blood.V106.11.2019.2019

Published: 2005

Journal Articles

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

Athanasios Anagnostopoulos, MD, Steven P. Treon, MD, Konstantinos Zervas, MD, Andrew Branagan, MD, Dimitra Gika, Athanasios Zomas, MD, Marie Christine Kyrtsonis, MD, Amalia Vassou, MD, Nikolaos Anagnostopoulos, MD, Gerasimos Pangalis, MD, Meletios A. Dimopoulos, MD

Blood (2005) 106 (11): 3485.

https://doi.org/10.1182/blood.V106.11.3485.3485

Published: 2005

Journal Articles

Prognostic Value of Serum β2-Microglobulin in Patients with Waldenstrom’s Macroglobulinemia Requiring Treatment.

Athanasios Anagnostopoulos, MD, Konstantinos Zervas, MD, Evangelos Terpos, MD, Marie Christine Kyrtsonis, MD, Argyris Symeonidis, MD, Dimitra Gika, Konstantinos Bourantas, MD, Athanasios Zomas, MD, Nikolaos Angnostopoulos, MD, Gerasimos Pangalis, MD, Meletios A. Dimopoulos, MD

Blood (2005) 106 (11): 3415.

https://doi.org/10.1182/blood.V106.11.3415.3415

Published: 2005

Journal Articles

Macrophage Inflammatory Protein-1 alpha (MIP-1α) Is Increased in Patients with Waldenstrom’s Macroglobulinemia and Correlates with the Severity of Disease.

Evangelos Terpos, MD, PhD, Athanasios Anagnostopoulos, MD, PhD, Efstathios Kastritis, MD, Aristotelis Bamias, MD, PhD, Konstantinos Tsionos, MD, Meletios A. Dimopoulos, MD, PhD

Blood (2005) 106 (11): 2498.

https://doi.org/10.1182/blood.V106.11.2498.2498

Published: 2005

Journal Articles

Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenstrom’s Macroglobulinemia: Correlations with Clinical Data.

Athanasios Anagnostopoulos, MD, PhD, Evangelos Terpos, MD, PhD, Efstathios Kastritis, MD, Aristotelis Bamias, MD, PhD, Konstantinos Tsionos, MD, Meletios A. Dimopoulos, MD, PhD

Blood (2005) 106 (11): 2504.

https://doi.org/10.1182/blood.V106.11.2504.2504

Published: 2005

Journal Articles

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

Evangelos Terpos, MD, PhD, Athanasios Anagnostopoulos, MD, PhD, Efstathios Kastritis, MD, Athanasios Zomas, MD, Christos Poziopoulos, MD, Nikolaos Anagnostopoulos, MD, PhD, Konstantinos Tsionos, MD, Meletios A. Dimopoulos, MD, PhD

Blood (2005) 106 (11): 363.

https://doi.org/10.1182/blood.V106.11.363.363

Published: 2005

Journal Articles

The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate.

Meletios A. Dimopoulos, MD, Efstathios Kastritis, MD, Lia A. Moulopoulos, MD, Ioannis Melakopoulos, MD, Athanasios Anagnostopoulos, MD, Dimitra Gika, George Bozas, MD, Vassiliki Koutsoukou, MD, Aristotelis Bamias, MD

Blood (2005) 106 (11): 637.

https://doi.org/10.1182/blood.V106.11.637.637

Published: 2005

Journal Articles

Prognostic Factors and Outcome of Older Patients with Symptomatic Multiple Myeloma: A Study of the Greek Myeloma Study Group (GMSG).

Athanasios Anagnostopoulos, MD, Dimitra Gika, Argiris Symeonidis, MD, Konstantinos Zervas, MD, Anastasia Pouli, MD, Panagiotis Repoussis, MD, Vassiliki Grigoraki, MD, Nikolaos Anagnostopoulos, MD, Alice G. Maniatis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2004) 104 (11): 4847.

https://doi.org/10.1182/blood.V104.11.4847.4847

Published: 2004

Journal Articles

Symptomatic Multiple Myeloma in Young Adults ≤ 40 Years of Age.

Argiris Symeonidis, MD, Anastasia Pouli, MD, Panagiotis Repoussis, MD, Konstantinos Zervas, MD, Athanasios Anagnostopoulos, MD, Chrysanthi Mitsouli, MD, Dimitra Gika, Alice Maniatis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2004) 104 (11): 4906.

https://doi.org/10.1182/blood.V104.11.4906.4906

Published: 2004

Journal Articles

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Meletios A. Dimopoulos, MD, Panagiotis Repoussis, MD, Evangelos Terpos, MD, Maria Christina Kyrtsonis, MD, Athanasios Zomas, MD, Eirini Katodritou, MD, Souzana Delibasi, MD, Amalia Vassou, MD, Athanasios Anagnostopoulos, MD, Anastasia Pouli, MD, Konstantinos Zervas, MD, Dimitrios Margaritis, MD, Nikolaos Anagnostopoulos, MD, Alice G. Maniatis, MD

Blood (2004) 104 (11): 1482.

https://doi.org/10.1182/blood.V104.11.1482.1482

Published: 2004

Journal Articles

Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow in Previously Untreated Patients with Multiple Myeloma.

Lia Angela Moulopoulos, MD, Dimitra Gika, MD, Kay Dellasale, Donna Weber, MD, Athanasios Anagnostopoulos, MD, Raymond Alexanian, MD, Meletios A. Dimopoulos, MD

Blood (2004) 104 (11): 1485.

https://doi.org/10.1182/blood.V104.11.1485.1485

Published: 2004

Journal Articles

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Meletios A. Dimopoulos, MD, Maria Christina Kyrtsonis, MD, Constantinos Tsatalas, MD, Garyfallia Kokkini, MD, Panagiotis Repoussis, MD, Athanasios Zomas, MD, Argiris Symeonidis, MD, Evridiki Michali, MD, Athanasios Anagnostopoulos, MD, Nikolaos Anagnostopoulos, MD, Theophanis Economopoulos, MD, Gerasimos Pangalis, MD

Blood (2004) 104 (11): 752.

https://doi.org/10.1182/blood.V104.11.752.752

Published: 2004

NARROW

Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.

The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM).

Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments.

Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens.

Long-Term Follow-Up of Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) for Patients (pts) with Chronic Myeloid Leukemia (CML).

Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenastrom’s Macroglobulinemia (WM): Correlations with Clinical Data.

Treatment of Low-Grade Non-Hodgkin Lymphomas with Fludarabine and Mitoxantrone Followed by Rituximab Maintenance: Results of a Phase II Study.

Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT).

Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens.

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

Prognostic Value of Serum β2-Microglobulin in Patients with Waldenstrom’s Macroglobulinemia Requiring Treatment.

Macrophage Inflammatory Protein-1 alpha (MIP-1α) Is Increased in Patients with Waldenstrom’s Macroglobulinemia and Correlates with the Severity of Disease.

Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenstrom’s Macroglobulinemia: Correlations with Clinical Data.

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate.

Prognostic Factors and Outcome of Older Patients with Symptomatic Multiple Myeloma: A Study of the Greek Myeloma Study Group (GMSG).

Symptomatic Multiple Myeloma in Young Adults ≤ 40 Years of Age.

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow in Previously Untreated Patients with Multiple Myeloma.

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only